First Foundation Inc. Reports Second Quarter 2025 Financial Results
The detailed earnings report and investor presentation can be accessed online at https://investor.ff-inc.com/financials/quarterly-results/default.aspx.
At 8 a.m. PT / 11 a.m. ET, Chief Executive Officer, Thomas C. Shafer, and Chief Financial Officer, Jamie Britton of First Foundation will host a discussion of the Company's financial results and performance and provide an update on recent activities.
The call will be broadcast live over the Internet and can be accessed using the link below First Foundation Q2 2025 Earnings Webcast. For those wishing to participate in the question-and-answer session, the call can be accessed by dialing in using the following toll-free number, 800-715-9871 and conference ID, 2340475.
About First Foundation
First Foundation Inc. (NYSE: FFWM) and its subsidiaries offer personal banking, business banking, and private wealth management services, including investment, trust, insurance, and philanthropy services. This comprehensive platform of financial services is designed to help clients at any stage in their financial journey. The broad range of financial products and services offered by First Foundation are more consistent with those offered by larger financial institutions, while its high level of personalized service, accessibility, and responsiveness to clients is more aligned with community banks and boutique wealth management firms. This combination of an integrated platform of comprehensive financial products and personalized service differentiates First Foundation from many of its competitors and has contributed to the growth of its client base and business. Learn more at firstfoundationinc.com or connect with us on LinkedIn and Twitter.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
34 minutes ago
- Yahoo
Why Hims & Hers Stock Sank This Week
Key Points Hims & Hers posted record revenue this quarter. It is still selling patented weight loss drugs on its platform and is now getting sued by the pharmaceutical companies. Investors would do best to avoid this stock until the legal battle is resolved. 10 stocks we like better than Hims & Hers Health › Shares of Hims & Hers (NYSE: HIMS) stock sank 17% this week, according to data from S&P Global Market Intelligence. The telehealth platform is delivering huge revenue growth but is at risk of a legal battle with weight loss drugmakers. Shares of the stock are down 25% from all-time highs but are up 400% in the past five years due to the platform's fast growth. Here's why the stock sank this week. Fast growth but a looming lawsuit In the second quarter of 2025, Hims & Hers' revenue grew 73% year over year to over $500 million, making it one of the fastest-growing companies in the world. This was driven by 30% growth in total subscribers to Hims & Hers products and 30% growth in spend per active subscriber. The company offers telehealth services for basic pharmaceuticals such as hair loss, sexual wellness, and weight loss drugs. While the company is growing quickly and now generating a profit, Hims & Hers is facing a looming legal battle with Novo Nordisk. The innovator in weight loss drugs originally had a partnership with Hims & Hers but pulled out of the deal because of disagreements over Hims & Hers selling knockoffs of its weight loss drug formula. Hims & Hers was permitted to sell patented weight loss drugs while they were in shortage, but now that the shortage is over, it is breaking the law by selling patented drugs to customers at a discount. Unsurprisingly, Hims & Hers is getting sued for this practice, which is a fast-growing part of its business. Investors are worried about the future impacts of this legal battle and how it could hurt Hims & Hers' future revenue growth and profitability. Should you buy Hims & Hers stock? Hims & Hers has been an incredible stock to own over the last few years, making shareholders rich. It has $2 billion in trailing revenue, up over 1,000% in the last five years. By far, it is the leading telehealth provider for drugs and medical treatments over the internet, making a ton of inroads in market share gains in the last few years. If there were no legal battle looming, Hims & Hers would probably be a buy on this dip. However, we cannot ignore the potential legal ramifications and huge risk Hims & Hers management is putting on itself and shareholders by blatantly selling patented weight loss drugs on its website. This legal battle is not likely to end well. Don't buy the dip on Hims & Hers stock until its dispute with the weight loss drugmakers is resolved. Do the experts think Hims & Hers Health is a buy right now? The Motley Fool's expert analyst team, drawing on years of investing experience and deep analysis of thousands of stocks, leverages our proprietary Moneyball AI investing database to uncover top opportunities. They've just revealed their to buy now — did Hims & Hers Health make the list? When our Stock Advisor analyst team has a stock recommendation, it can pay to listen. After all, Stock Advisor's total average return is up 1,047% vs. just 181% for the S&P — that is beating the market by 865.68%!* Imagine if you were a Stock Advisor member when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $636,563!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,108,033!* The 10 stocks that made the cut could produce monster returns in the coming years. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 4, 2025 Brett Schafer has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Hims & Hers Health. The Motley Fool recommends Novo Nordisk. The Motley Fool has a disclosure policy. Why Hims & Hers Stock Sank This Week was originally published by The Motley Fool
Yahoo
an hour ago
- Yahoo
Meet the 7.3% Yield Dividend Stock That Could Soar in 2026
Key Points Pfizer is doing well enough to pay down debt while sustaining its generous dividend. Oncology and specialty drugs are driving growth. The stock has a high ceiling heading into next year. 10 stocks we like better than Pfizer › It's been a tough stretch for pharmaceutical giant Pfizer (NYSE: PFE). The company enjoyed a vaccine windfall during the COVID-19 pandemic, but revenue and profits cratered as the pandemic eased and those tailwinds stopped blowing. The stock has tumbled, sending Pfizer's dividend yield to a whopping 7.3%. But Pfizer's stock price recently bounced on its second-quarter earnings. Investors have been looking for a glimpse into Pfizer's future, and there is a lot to like as things begin to come into view. Here is why Pfizer's newfound momentum could set the stock up to soar in 2026. Prudent financial management secures a generous dividend Pfizer's generous dividend has become a big reason why many people consider owning the stock. It's not easy to find a 7.3% dividend yield, and oftentimes, stocks that do are yield traps with significant underlying risks. While the market's negative sentiment toward Pfizer and the company's post-pandemic struggles have driven the share price down and the yield higher, the dividend itself is on solid footing. Management has raised the dividend for 15 consecutive years, so losing those pandemic-related profits didn't force a dividend cut. Additionally, the current dividend of $1.72 per share is well below the mid-point of management's 2025 adjusted EPS guidance of $3 per share. In other words, Pfizer is still earning plenty of money to afford its dividend, and is using that cushion to, wisely, pay down debt to improve its balance sheet. That's prudent financial leadership, and should give investors some confidence that they can count on the stock's robust 7.3% yield as a nice baseline for the stock's future returns. Is Wall Street sleeping on Pfizer's growth? It seems the broader market is cautious toward healthcare stocks at the moment. Not only could tariffs raise costs for drug companies, but there is also pressure from the Trump administration to cut prescription drug prices for Americans. However, Pfizer seems to be increasingly confident that it can navigate these headwinds and grow its business. Management recently raised its 2025 adjusted earnings guidance from a range of $2.80 to $3.00 per share to $2.90 to $3.10. The company has focused its growth efforts on oncology and specialty drugs, which are less likely to face pricing pressure. And that's precisely where Pfizer is growing the most; the company's specialty drug sales are up 6% year over year, and oncology sales are up 9% through six months of 2025. As specialty and oncology drug sales increase, they should have a greater effect on Pfizer's overall growth. These two segments combined for approximately $16.5 billion through six months of this year. Pfizer's primary care drug sales, totaling $11.2 billion, are down 8% year over year as COVID-19 sales continue to fall off. Six-month sales of Pfizer's COVID-19 drugs are now less than $2 billion, so their impact on the numbers is drying up. Additionally, Pfizer's top seller, Eliquis, faces patent expiration but likely won't face generic competition until at least 2028. Analysts only anticipate Pfizer earning $3.10 per share next fiscal year, but that could be too conservative, given Pfizer's momentum in oncology and specialty drugs and the resulting boost to this year's guidance. It seems tariff and political concerns are weighing on short-term expectations. If you zoom out, analysts anticipate Pfizer growing earnings at an annualized rate of 9% over the next three to five years, which seems to underline the good things happening in the business. The conditions are ripe for a dramatic sentiment boost, making Pfizer a coiled spring at its current price So, what does this all mean? There's an argument that Pfizer's stock could face a boost in sentiment if the dark clouds (tariffs and political pressure) clear out, allowing investors to refocus on Pfizer's growth in oncology and specialty drugs. Today, Pfizer trades at just 8 times the midpoint of its 2025 earnings guidance. That valuation resembles a company on the verge of going under, not one that could grow at a high-single-digit pace over the coming years. Even if the valuation stays the same, Pfizer needs very little growth to generate double-digit investment returns because the dividend starts you off at over 7%. If things do go well and Wall Street warms up to Pfizer, the stock could produce some seriously outsized returns from a lucrative trifecta of: A 7.3% dividend Potential high-single-digit growth A valuation that could soar with some positive sentiment It makes Pfizer a fantastic choice for income-focused investors, as well as bargain hunters looking for some upside in a market already trading at all-time highs, chugging toward 2026. Should you invest $1,000 in Pfizer right now? Before you buy stock in Pfizer, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Pfizer wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $653,427!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,119,863!* Now, it's worth noting Stock Advisor's total average return is 1,060% — a market-crushing outperformance compared to 182% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 4, 2025 Justin Pope has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Pfizer. The Motley Fool has a disclosure policy. Meet the 7.3% Yield Dividend Stock That Could Soar in 2026 was originally published by The Motley Fool
Yahoo
an hour ago
- Yahoo
Energy Transfer's Record-Breaking Performance Continues
Key Points Energy Transfer set several volume records in the second quarter. The MLP's earnings growth slowed due to fewer growth catalysts and commodity price headwinds. It has several growth catalysts ahead in 2026 and beyond. 10 stocks we like better than Energy Transfer › Energy Transfer (NYSE: ET) recently reported its second-quarter financial and operational results. The company's energy midstream operations were firing on all cylinders during the period, as evidenced by the numerous volume records it set. While its earnings growth rate slowed in the quarter, a re-acceleration awaits. Here's a closer look at the master limited partnership's (MLP) second-quarter results and outlook for what's ahead. Drilling down into Energy Transfer's second-quarter results Energy Transfer generated nearly $3.9 billion of adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA) during the second quarter. That was about 3% higher than the year-ago period. Meanwhile, its distributable cash flow (DCF) dipped 4% to nearly $2 billion. While the company's growth rates have slowed from last year, when its adjusted EBITDA rose 13% and its DCF increased by 10% to new partnership records (fueled by several acquisitions), a re-acceleration is right around the corner. Here's a snapshot of its earnings by segment: As the chart shows, Energy Transfer got boosts from its interstate transportation and storage and midstream segments. It also benefited from its investment in Sunoco LP, which contributed substantial additional income in the period following its acquisition of NuStar. This helped offset lower earnings in its crude oil, NGL (natural gas liquids), and intrastate segments due to the impact of lower commodity prices and higher expenses. While those headwinds caused the MLP's earnings growth rates to slow in the second quarter, its volumes continued to rise. It set new partnership records in the following categories during the period: Midstream gathered volumes (up 10%) Crude oil transportation volumes (up 9%) NGL transportation volumes (up 4%) NGL and refined products terminal volumes (up 3%) NGL exports (up 5%) The midstream company benefited from healthy market conditions and the residual impact of recent expansion initiatives, including last year's acquisition of WTG Midstream. Lots of growth is coming down the pipeline Continued commodity price headwinds will likely mute Energy Transfer's earnings growth rate through the second half of the year. The MLP currently expects its adjusted EBITDA to be at or slightly below the lower end of its 2025 guidance range of $16.1 billion-$16.5 billion. That implies about 4% growth from last year's level. However, it has a lot of momentum heading into 2026 and beyond. Energy Transfer recently placed its Lenorah II and Badger processing plants into service. It has also placed its Nederland Flexport NGL Export Expansion project into ethane and propane services, with ethylene service expected in the fourth quarter. These projects will supply it with incremental earnings in the coming quarters. The company should also get a boost from Sunoco's pending acquisition of Parkland, which should close later this year. Meanwhile, there are more expansion projects on the way next year. The company expects to put its Mustang Draw gas processing plant into service in the second quarter and finish Phase I of its major Hugh Brinson gas pipeline and Frac IX by the end of the year. These projects will give it a lot of earnings growth momentum throughout 2026 and into 2027. Additionally, Energy Transfer has secured several new expansion projects that enhance and extend its growth outlook through the end of the decade. It recently approved Hugh Brinson Phase II (constructed concurrently with Phase I), the Delaware Basin NGL Pipe Looping project (first half of 2027), the Bethel Storage Expansion (late 2028), and the $5.3 billion Transwestern Pipeline (fourth quarter 2029). These projects will provide it with incremental sources of growing cash flow into the next decade. The midstream giant has several more proposed expansion projects under development, including the long-delayed Lake Charles LNG export terminal and the CloudBurst AI data center gas supply project. Securing these and other expansions would further enhance and extend the company's long-term growth outlook. In addition to its organic growth, Energy Transfer has ample financial flexibility to continue making strategic acquisitions as opportunities arise. Future deals would help further bolster its already strong growth profile. A solid quarter with a growth acceleration ahead Energy Transfer delivered solid second-quarter results as growing volumes helped mute the impact of lower commodity prices. While that headwind will likely slow its growth this year, a major wave of expansion projects should reinvigorate the company in 2026 and beyond. That growth should give it plenty of fuel to continue increasing its 7.5%-yielding distribution. It makes the MLP an enticing investment opportunity for those seeking income and growth, and who are comfortable receiving the Schedule K-1 Federal Tax Form it sends each year and doing what's needed with that. Should you buy stock in Energy Transfer right now? Before you buy stock in Energy Transfer, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Energy Transfer wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $636,563!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,108,033!* Now, it's worth noting Stock Advisor's total average return is 1,047% — a market-crushing outperformance compared to 181% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 4, 2025 Matt DiLallo has positions in Energy Transfer. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. Energy Transfer's Record-Breaking Performance Continues was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
